资料显示，中牧实业股份有限公司位于北京市丰台区南四环西路188号八区16-19号楼，成立日期1998年 12月25日，上市日期1999年1月7日，公司主营业务涉及动物保健品,包括畜禽用疫苗、诊断液、兽药等 几大类。动物营养品:包括饲料原料、饲料添加剂、预混合饲料及大宗饲料原料的进出口贸易。主营业 务收入构成为：化药35.78%，贸易27.87%，饲料19.21%，生物制品16.10%，其他1.04%。 中牧股份所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：禽流感药物、兽 药、年报预增、宠物经济、病毒防治等。 2月24日，中牧股份盘中上涨2.09%，截至13:43，报7.83元/股，成交6372.50万元，换手率0.80%，总市 值79.96亿元。 资金流向方面，主力资金净流入208.71万元，特大单买入755.45万元，占比11.85%，卖出151.59万元， 占比2.38%；大单买入1138.46万元，占比17.87%，卖出1533.62万元，占比24.07%。 中牧股份今年以来股价跌0.51%，近5个交易日跌1.26%，近20日跌7.77%，近60日跌0.13%。 机构持仓方面，截止 ...

财务数据显示，截至2025年末，公司总资产预计达4.34亿元，较期初增长10.39%，主要源于生猪养殖业务的资产投入。但归属于上市公司股东的所有者权 益为2.65亿元，较期初下降9.81%；每股净资产降至2.39元。加权平均净资产收益率为-10.32%，较上年同期进一步下滑。 2月9日晚间，北交所上市公司山西大禹生物工程股份有限公司发布2025年度业绩快报。 报告期内，公司实现营业收入1.68亿元，同比增长36.78%；但归属于上市公司股东的净利润亏损2878.57万元，较上年同期亏损幅度扩大20.23%。这也是 公司自2023年以来第三年亏损。 业绩快报显示，大禹生物2025年营收增长主要得益于新拓展的生猪养殖业务。该板块全年贡献营收4218.97万元，成为公司收入增量的核心来源。然而， 正是这项新业务拖累了整体盈利能力。公司解释称，受生猪养殖行业周期性波动影响，2025年第四季度生猪市场价格大幅回落，导致养殖业务板块未能实 现盈利，直接造成公司净利润亏损较上年同期增加484.30万元。 除养殖业务亏损外，公司传统饲料添加剂、饲料及兽药等存量业务亦面临挑战。近年来，受行业产能调控和非洲猪瘟疫情影响，生猪养殖 ...

Investment Rating - The report maintains an "Outperform" rating for the agriculture, forestry, animal husbandry, and fishery industry [1][4]. Core Views - The report anticipates a reversal in the livestock cycle, particularly benefiting Hong Kong dairy farming stocks [1]. - The monthly recommended stock portfolio includes leading companies in various segments: Yuran Agriculture, Modern Farming, Muyuan Foods, Dekang Agriculture, and Lihua Co., among others [1][3]. - The report highlights the expected upward trend in domestic beef and milk prices, driven by a recovery in the livestock cycle and improved cash flow for leading companies [1][14]. Summary by Sections Livestock Sector - The livestock sector is expected to experience a significant turnaround, with recommendations for Yuran Agriculture and Modern Farming as key beneficiaries [1][14]. - The report notes that domestic beef production capacity is decreasing, which may lead to price increases through 2028 [14]. - The improvement in raw milk prices is anticipated to benefit dairy farming companies, with a projected profit increase for Yuran Agriculture and Modern Farming [17]. Swine Sector - The swine sector is highlighted for its potential recovery, with leading companies like Huazhong, Dekang Agriculture, and Muyuan Foods recommended for investment [1][14]. - The report indicates that the industry is moving towards a more stable price center, supported by a reduction in production capacity and improved cash flow for leading firms [15][20]. Poultry Sector - The poultry sector is expected to see a recovery in demand, with recommendations for Lihua Co. and Shengnong Development [1][18]. - The report notes that the supply of white feather chickens is increasing, but demand is expected to improve, leading to potential price recovery [22][24]. Pet Sector - The pet food market is identified as a growing segment, with a focus on domestic brands like Guibao Pet [1][16]. - The report emphasizes the long-term growth potential of the pet sector, driven by rising consumer sentiment and market expansion [16]. Feed Sector - The feed sector is expected to benefit from deeper industrialization in livestock farming, with leading companies like Haida Group recommended [1][18]. - The report notes that feed prices are at historical lows, providing a strong support level for future price recovery [18].

Core Viewpoint - Limin Co., Ltd. (002734) is experiencing significant growth, with a projected net profit increase of 471.55%-514.57% for 2025 compared to the previous year, indicating strong demand and operational efficiency [1] Group 1: Company Overview - The company offers a diverse range of products including bactericides, insecticides, herbicides, veterinary drugs, soil conditioners, and seed coatings [1] - Limin Co., Ltd. has consistently achieved over 4 billion yuan in annual revenue from 2020 to 2024 [1] Group 2: Financial Projections - The forecast for the annual net profit attributable to shareholders in 2025 is estimated to be between 465 million yuan and 500 million yuan [1] - This represents a substantial growth rate compared to the previous year's performance [1] Group 3: Operational Status - The company reports a strong order backlog and is currently operating at full production and sales capacity [1]

Core Viewpoint - The company, *ST Green Health, is expected to report a negative net profit for the fiscal year 2025, marking the first accounting year after the implementation of financial delisting risk warning on its stock [1][10]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025, with an anticipated net profit being negative [1]. - The company has completed a significant asset restructuring, transferring 100% equity of three subsidiaries to another company, which will affect the financial results [2]. Group 2: Communication with Auditors - The company has communicated with its auditing firm regarding the performance forecast, and there are no significant disagreements as of the announcement date [3]. Group 3: Reasons for Performance Changes - The main reason for the performance change is the separation of the loss-making photovoltaic film business, which will no longer be included in the consolidated financial statements [4]. - Despite the expected loss, the veterinary medicine business has seen revenue growth, primarily from higher-margin products, leading to an overall improvement in gross margin compared to 2024 [4]. Group 4: Risk of Delisting - The company reported a negative net asset value of -24,536,065.37 yuan as of the end of 2024, triggering a delisting risk warning [10][14]. - The net profits attributable to shareholders for 2022, 2023, and 2024 were -121,938,109.79 yuan, -221,817,878.58 yuan, and -444,864,018.29 yuan respectively, indicating a continuous decline [11][14]. - If the company’s financial indicators trigger delisting rules again in 2025, the stock may face termination of listing [24]. Group 5: Audit Progress - The auditing firm, Lixin, has been conducting the 2025 annual audit since November 2025, and there are no major disagreements on significant accounting treatments or key audit matters [25][26]. - The company is actively progressing with the preparation and auditing of the 2025 annual report [25].

Core Viewpoint - *ST Lvkang (002868.SZ) expects a net profit attributable to shareholders of the listed company to be between -140 million and -125 million yuan for 2025, with operating revenue projected to be between 500 million and 515 million yuan [1] Group 1: Financial Performance - The main reason for the company's performance change this year is the expected positive equity attributable to shareholders due to the divestiture of the severely loss-making photovoltaic film business in 2025, which will no longer be included in the consolidated financial statements [1] - The net profit attributable to shareholders is still expected to be a loss primarily due to the losses incurred by the photovoltaic film business before its divestiture, which accounted for over 90% of the losses [1] - The veterinary medicine business has seen revenue growth this year, mainly driven by higher-margin products and an optimized product structure, resulting in an overall improvement in gross margin compared to 2024 [1]

格隆汇1月27日丨*ST绿康(002868.SZ)公布，预计2025年归属于上市公司股东的净利润-14,000万元 ～-12,500万元，扣除非经常性损益后的净利润-14,000万元～-12,900万元，营业收入50,000万元～51,500 万元。 公司本年业绩变动的主要原因是：1、公司本年归属于上市公司股东的所有者权益转正主要原因系2025 年将亏损严重的光伏胶膜业务剥离，剥离后光伏胶膜子公司不再纳入上市公司合并报表范围。2、本年 归属于上市公司股东的净利润仍为亏损主要系由光伏胶膜业务在剥离前的亏损导致，光伏胶膜子公司的 亏损占比在90%以上。3、本年兽药业务收入有所增长，增长部份主要来源于毛利较高产品，加上产品 结构的优化，整体毛利率水平较2024年有所提升。 ...

Core Viewpoint - The article highlights the dedication and achievements of Du Jihong, a key figure in the veterinary drug quality and animal product safety monitoring in Beijing, emphasizing her role in ensuring food safety and regulatory compliance in the livestock industry [3][4][8]. Group 1: Monitoring and Regulatory Achievements - Du Jihong has been instrumental in leading veterinary drug monitoring efforts, overseeing the inspection of 151 veterinary drug products across 66 enterprises and farms, which has contributed to a high compliance rate in Beijing [4][5]. - Under her leadership, a total of 230 monitoring subjects were tested nearly 4,000 times, successfully identifying illegal additives in veterinary drugs [4][5]. - The establishment of a "1+4+5" tiered monitoring system has allowed for precise management of 18 large-scale breeding enterprises, significantly enhancing the efficiency and accuracy of bacterial resistance monitoring [5][6]. Group 2: Event Support and Emergency Preparedness - During the Beijing 2022 Winter Olympics, Du Jihong led the livestock product safety team, implementing a comprehensive monitoring mechanism that ensured zero errors in product safety during the event [6][7]. - She developed detailed testing plans and sampling protocols, conducting over 20 sampling surveys and completing 386 batches of livestock product tests [6][7]. Group 3: Training and Capacity Building - Du Jihong has organized over 5,000 training sessions for industry professionals, significantly improving the overall monitoring capabilities within the sector [6][7]. - Her efforts in training have led to notable achievements in national skill competitions, showcasing the enhanced skills of participants [6][7]. Group 4: Safety and Risk Management - A strong emphasis on safety has been a hallmark of Du Jihong's work, with the implementation of a three-tier inspection mechanism and the establishment of safety management protocols, resulting in zero accidents at the monitoring center [7][8]. - The proactive approach to safety includes distributing safety manuals and conducting on-site safety checks, contributing to a culture of safety within the veterinary drug industry [7][8].

Group 1 - The core viewpoint of the news is that Limin Co., Ltd. has shown significant financial performance and trading activity, with a notable increase in net profit and a stable financing situation [1][2] Group 2 - On January 15, Limin Co., Ltd. saw a stock price increase of 2.03%, with a trading volume of 493 million yuan. The financing buy-in amount for the day was 99.19 million yuan, while the financing repayment was 43.02 million yuan, resulting in a net financing buy-in of 56.18 million yuan [1] - As of January 15, the total financing and securities balance for Limin Co., Ltd. was 426 million yuan, which accounts for 5.24% of its circulating market value [1] - The company had no shares repaid in the securities lending market on January 15, with 100 shares sold, amounting to 1,710 yuan at the closing price, and a remaining securities lending balance of 900 shares valued at 15,400 yuan [1] Group 3 - As of December 31, the number of shareholders for Limin Co., Ltd. was 56,100, a decrease of 2.03% from the previous period, while the average circulating shares per person increased by 10.12% to 7,747 shares [2] - For the period from January to September 2025, Limin Co., Ltd. achieved an operating income of 3.599 billion yuan, representing a year-on-year growth of 7.62%, and a net profit attributable to shareholders of 390 million yuan, which is a remarkable increase of 661.66% [2] - Since its A-share listing, Limin Co., Ltd. has distributed a total of 918 million yuan in dividends, with 321 million yuan distributed over the past three years [2]

Group 1 - The core viewpoint of the news is that Reap Bio has been recognized as a "Green Factory" for 2025 by the Tianjin Municipal Bureau of Industry and Information Technology, highlighting its leadership in promoting green transformation in the industry [1] - The recognition reflects Reap Bio's strong manufacturing capabilities and its commitment to integrating green and low-carbon development into its core business strategy since its establishment [1] - The evaluation process for the recognition included stringent requirements on energy consumption levels, environmental indicators, and green management systems, prioritizing enterprises with a solid foundation in green low-carbon development [1] Group 2 - In recent years, Reap Bio has aimed to build "smart factories and digital factories," implementing a lean green management system and increasing investments in the integration of intelligence, digitalization, and greening [2] - The company has embedded low-carbon standards throughout the entire process from raw material procurement to production and finished product delivery, utilizing smart production equipment and real-time monitoring systems for energy consumption and emissions [2] - Reap Bio's practices align with the national "14th Five-Year Plan" recommendations to accelerate the high-end, intelligent, and green development of the manufacturing industry, and the company plans to continue its commitment to sustainable development and contribute to high-quality manufacturing and carbon neutrality goals [2]